Administration control methods for tumor cell inhibition

By combining model smoothing super-twist control and conventional super-twist control algorithms, a tumor cell drug delivery controller was designed, which solved the chattering problem of the first-order sliding mode controller, achieved the stability and accuracy of the tumor cell drug delivery system, reduced the side effects of healthy cells, and enhanced the anti-interference ability.

CN116631599BActive Publication Date: 2026-11-17SHENZHEN TECH UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310584793.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2026-11-17
Estimated Expiration
2043-05-22

AI Technical Summary

Technical Problem

In the prior art, the first-order sliding mode controller inevitably exhibits jitter during tumor cell drug delivery, leading to instability of the drug delivery system, making it difficult to accurately control the delivery of drugs to tumor cells, and causing side effects on healthy cells.

Method used

A drug delivery control method based on a hybrid model-smoothed super-twisted control and conventional super-twisted control algorithms is adopted. By constructing a mathematical model of tumor cells, a drug delivery controller suitable for tumor cell inhibition is designed. A continuous function is used to replace the discontinuous switching function, and Lyapunov function is used for stability analysis to ensure the asymptotic stability of the system.

Benefits of technology

This reduces the impact of vibration on the stability of the tumor cell drug delivery system, improves the accuracy of drug delivery, reduces the side effects on healthy cells, enhances anti-interference ability, and achieves stability and effectiveness of the tumor suppression drug delivery system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116631599B_ABST
    Figure CN116631599B_ABST
Patent Text Reader

Abstract

This invention discloses a drug delivery control method applicable to a mathematical model of tumor cells, comprising: constructing a mathematical model of tumor cells; determining the control objective as using a specific drug delivery time and / or dosage to ensure that the mathematical model of tumor cells can control the growth pattern of tumor volume; determining the control objective, designing a smooth super-torsion controller using a model-based smooth super-torsion control method, and designing control laws for the smooth super-torsion controller parameters and uncertain parameters of the drug delivery system to obtain a control law based on the smooth super-torsion control algorithm; and designing a control law based on a hybrid of conventional super-torsion control algorithm and model smooth super-torsion control algorithm. This invention is not limited by the conditions of disturbance terms in traditional drug delivery control systems, ensuring convergence under disturbance conditions. Furthermore, the combination of smooth super-torsion control can effectively suppress chattering, improve system performance, enhance the robustness of the drug delivery system to uncertainties and external disturbances, and ensure system stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of drug delivery control technology for cell inhibition, and in particular to a drug delivery system control method based on a hybrid algorithm of super-twisted control and smooth super-twisted control. Background Technology

[0002] Cancer has become the second leading cause of death after cardiovascular disease. Current treatments for cancer include radiation therapy, surgery, chemotherapy, and immunotherapy. These methods are used to eliminate or reduce cancer cells in the body.

[0003] Chemotherapy is a commonly used method for treating cancer. To study the effects of radiotherapy, researchers construct tumor cell models to simulate the growth process of tumor cells and healthy cells. They then adjust certain parameters of the tumor cell models to determine the effectiveness of radiotherapy. However, while drugs kill cancer cells, they also kill a certain number of healthy cells, causing side effects. Therefore, precisely controlling the delivery of drugs to tumor cell models to avoid killing healthy cells and reduce side effects is a challenge in this research field.

[0004] Existing technologies use first-order sliding mode controllers to control the drug delivery process. Although traditional first-order sliding mode controllers have discontinuous switching capabilities and theoretically possess strong anti-interference capabilities, the switching function inevitably leads to chattering, causing instability in the drug delivery system.

[0005] Therefore, how to provide a stable method for drug delivery control in tumor cell models is a technical problem to be solved. Summary of the Invention

[0006] To address the chattering problem inherent in first-order sliding mode controllers caused by switching functions in existing technologies, this invention proposes a tumor cell model drug delivery control method based on model smoothing super-twisting control.

[0007] The tumor cell model drug administration control method proposed in this invention includes:

[0008] 1) Construct a mathematical model of tumor cells;

[0009] 2) The control target is to use specific administration time and / or dosage to ensure that the tumor cell model can control the growth pattern of tumor volume;

[0010] 3) Based on the defined control objective, a first drug delivery controller model suitable for tumor cell inhibition is designed using the conventional super-twisted control algorithm, and a control law based on the conventional super-twisted control algorithm is designed.

[0011] 4) Design a second drug delivery controller model suitable for tumor cell inhibition based on the model-based smooth super-twisting control (MBSSTC) algorithm and the conventional super-twisting control algorithm, and design a control law based on a hybrid of the conventional super-twisting control algorithm (STC algorithm) and the model-based smooth super-twisting control (MBSSTC algorithm).

[0012] Furthermore, the mathematical model for tumor cells includes at least the logarithmic death model dx / dt = -rxln(x) - δxu(t), the Norton-Simon model dx / dt = -ln(x) [rx - δu(t)], and the Emax model.

[0013] Where x is the tumor volume, r is the tumor volume growth rate, δ represents the coefficient related to the amount of drug used, λ represents the model constant, and u(t) represents the drug concentration controlled at time t.

[0014] Furthermore, without considering external interference, the first drug delivery control model suitable for tumor cell inhibition is:

[0015] Taking external interference into account, the second drug administration control model suitable for tumor cell inhibition is as follows:

[0016] Where x(t) represents tumor volume, u(t) represents control input, d(t) represents external disturbance, and f(x) represents the tumor cell model, where f(x) is represented as -rxln(x) in the logarithmic death model, g(x) is represented as δx in the logarithmic death model, f(x) is represented as -rxln(x) in the Norton-Simon model, g(x) is represented as δln(x) in the Norton-Simon model, f(x) is represented as -rxln(x) in the Emax model, and g(x) is represented as...

[0017] Furthermore, the control law design based on the conventional super-twist control algorithm is as follows:

[0018] u:

[0019] Where k1 and k2 are adjustable gain parameters, and e represents a finite-time convergence function.

[0020] Furthermore, the control law design based on the hybrid of conventional super-twist control algorithm and model smoothing super-twist control algorithm is as follows:

[0021]

[0022] Where k1 and k2 represent the parameters of the super-twist controller, k1>0, k2>0, ε represents the adjustable parameter, and e represents the finite-time convergence function.

[0023] Furthermore, the tracking error of tumor volume is defined as: e(t) = x(t) - x d (t); where x d This is the expected value for tumor growth, with a maximum value of 1;

[0024] The first derivative of the tracking error and dosing control model is: Substituting the control law based on a hybrid of conventional and model-smoothed super-twisted control algorithms into the formula corresponding to the tracking error, we obtain the system dynamics formula:

[0025] Where η1=e, e represents a finite-time convergent function that converges to the optimal solution within a finite time, and η2 is the calculus of η1 over time.

[0026] Furthermore, it also includes the following steps:

[0027] 5) The second drug delivery controller model is subjected to stability analysis by using a quadratic-like Lyapunov function under constant and variable perturbations to ensure the asymptotic stability of the system.

[0028] Furthermore, stability analysis includes the following steps:

[0029] Based on the first definition and the first to fourth lemmas, it is proved that the states η1 and η2 of the system will approach the following regions:

[0030]

[0031] Where k1 and k2 are positive constants, and φ∈(0,1) is a constant that must be small enough;

[0032] The first definition is: given a vector x = [x1, x2, x3, ..., x...] n ]∈R n and the constant τ i >0, i=1,2,…,n. If p∈R, and definition Then the function R n →R, where τ=[τ1,τ2,…,τ n [] represents the weights of the states. R is a positive definite matrix function;

[0033] The first lemma states that: positive definite functions R n →R and function Φ(x):R n →R For the same dilation weight, R has the same uniformity, and there exists a constant and If is positive definite, then where k ≥0;

[0034] The second lemma is: Assume 0<a≤1, then |[x] a -[y] a |≤2 1-a |x-y| a ;

[0035] The third lemma is: Let m>0, n>0, then for it can be obtained that:

[0036] where h(x,y) is a positive function;

[0037] The fourth lemma is: Let b≥1, then for the following holds:

[0038] |[x] b -[y] b |≤b(2 b-2 +2)(|x-y| b +|x-y||y| b-1 ;

[0039] |[x] b -[y] b |≥2 1-b |x-y| b ;

[0040] It needs to be proved that

[0041] The region Q1 is constructed as:

[0042]

[0043] Since it can be derived that

[0044] From the first definition, it is obtained that and are homogeneous of degree 1-γ, related to the dilation weight (1, 1+ε);

[0045] By using the first lemma, the inequality conclusion is drawn:

[0046] Substituting the conclusion of the inequality into get:

[0047]

[0048] Based on facts get:

[0049]

[0050] For any initial state (x1(0), x2(0)) ∈ Q2, the region ensures the existence of a time instance T such that (x1, x2) ∈ Q2.

[0051] Q2 is defined as:

[0052]

[0053] Considering the first definition, H(x1,x2) is a homogeneous 2+ε degree with respect to the inflation weight (1, 1+ε);

[0054] Using the first lemma, we can conclude that:

[0055]

[0056]

[0057] Restate the conclusion obtained using the first lemma to get:

[0058]

[0059] Based on the above formula, we get (x1,x2)∈Q2, that is...

[0060] Alternatively, there exists a finite-time instance T such that V(x1,x2)≤K.

[0061] When t≥T, we can obtain:

[0062]

[0063] because a1 = k1, from the above formula we can deduce:

[0064]

[0065] On the other hand, when t≥T, we get:

[0066]

[0067] Considering x1 = η1, we can conclude that:

[0068]

[0069] Based on the above formula, it can be determined that the system states η1 and η2 will be driven and converge to the region Ω within a finite time.

[0070] The above-mentioned technical solution proposed by the present invention for tumor cell models in drug delivery systems has the following beneficial effects.

[0071] 1. The drug delivery control scheme based on the hybrid SCT and MBSTC algorithms replaces the discontinuous switching function used in the traditional SCT control algorithm with a continuous function, reducing the impact of chattering on the stability and accuracy of the tumor cell drug delivery system.

[0072] 2. By designing appropriate controller parameters, the error between the predicted tumor growth volume and the actual tumor growth volume can be reduced, thereby ensuring the effectiveness of the tumor suppression drug delivery system.

[0073] 3. The proposed tumor suppression drug delivery system control scheme based on a hybrid SCT and MBSTC algorithm can serve as a novel approach to reclassify SCT control and PI controllers. By selecting appropriate parameters, the necessary anti-interference capability and tumor volume performance can be achieved. Attached Figure Description

[0074] The present invention will now be described in detail with reference to the embodiments and accompanying drawings, wherein:

[0075] Figure 1 This is the main flowchart of the present invention;

[0076] Figure 2(a) shows the tumor volume response process of the STC controller.

[0077] Figure 2(b) shows the tumor volume response process of the MBSTC controller. Detailed Implementation

[0078] To make the technical problems to be solved, the technical solutions, and the beneficial effects of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0079] Therefore, a feature pointed out in this specification is used to describe one feature of one embodiment of the invention, and does not imply that every embodiment of the invention must have the described feature. Furthermore, it should be noted that this specification describes many features. Although certain features may be combined to illustrate possible system designs, these features may also be used in other combinations not explicitly stated. Therefore, unless otherwise stated, the described combinations are not intended to be limiting.

[0080] The drug administration control method for tumor cell models proposed in this invention mainly includes the following steps.

[0081] Step 1: Construct a mathematical model of tumor cells;

[0082] Step 2: Determine the control target by using specific dosing times and / or dosages to ensure that the tumor cell model can control the growth pattern of tumor volume;

[0083] Step 3: Based on the determined control objective, design a first drug delivery control model suitable for tumor cell inhibition using the conventional super-twisting control (STC) algorithm, and design the control law u(t) based on the conventional super-twisting control algorithm;

[0084] Step 4: Design a second drug delivery controller model suitable for tumor cell inhibition based on the model smoothing super-twisting control algorithm and the conventional super-twisting control algorithm, and design a control law u(t) based on a hybrid of the STC algorithm and the MBSSTC algorithm.

[0085] In a preferred embodiment, step 5 may be further included, using a quadratic-like Lyapunov function to perform stability analysis on the above-mentioned tumor cell inhibition drug delivery control system (including the above-mentioned drug delivery control model and its control law) under constant value perturbation and variable value perturbation, respectively, to ensure the asymptotic stability of the system.

[0086] I. Mathematical Model of Tumor Cells

[0087] In step 1 above, existing tumor cell models can be used, which can simulate the growth and death processes of tumor cells.

[0088] In one specific embodiment of the present invention, the mathematical model of tumor cells includes at least the logarithmic death model, the Norton-Simon model, and the Emax model.

[0089] The logarithmic death model reduces cancer cells in a logarithmic manner.

[0090] In the Norton-Simon model, the regression rate (tumor regression rate) was directly proportional to the immediate growth rate of untreated tumors upon first use. Faster-growing tumors exhibited higher regression rates than slower-growing tumors. This reinforced the idea that rapidly growing cancer cells, which require less drug administration in their early stages, were killed.

[0091] The Emax model represents the relationship between drug dosage and drug effect.

[0092] In this embodiment, the mathematical models of the three types of tumor cells can be described by the following three formulas.

[0093] Logarithmic mortality model: dx / dt=-rxln(x)-δxu(t) (1)

[0094] Norton-Simon model: dx / dt = -ln(x)[rx - δu(t)] (2)

[0095] Emax model:

[0096] Where x is the tumor volume, r is the tumor volume growth rate, δ represents the coefficient related to the amount of drug used, and λ represents the model constant, which can also be called the function constant.

[0097] u(t) represents the drug concentration delivered at time t. When the drug concentration delivered at time t is 0, u(t) = 0 indicates that the cells are not using the drug, while when the drug concentration delivered at time t is greater than 0, u(t) > 0 indicates that the drug concentration is being used. Furthermore, when the initial time t = 0, given the tumor volume x(0) = x0, where 0 < ... <x0<1。

[0098] In step 2 above, the growth trajectory of the tumor volume is designed as x. d (t). When drugs are introduced into a tumor cell model, the tumor volume should decrease or reach a safe level. This can be achieved, for example, by using specific dosing times, specific dosages, or specific dosages administered at specific times. Therefore, it is necessary to ensure that the constructed cell model can control the growth trajectory of the tumor volume. d (t).

[0099] II. Tumor Cell Inhibition Drug Administration Control Model

[0100] In step 3 above, the design of a tumor cell inhibition drug delivery control model based on the STC algorithm, based on the determined control objective, can be obtained through the following steps.

[0101] Without considering external interference, design a first drug delivery control model suitable for tumor cell models:

[0102]

[0103] Considering external interference, a second drug administration control model suitable for tumor cell models was designed:

[0104]

[0105] Where x(t) represents the tumor volume, u(t) represents the control input, d(t) represents the external interference, and f(x) represents the tumor cell model, which can be represented by formulas (1)-(3), as shown below.

[0106] In the logarithmic death model, f(x) is represented as -rxln(x), and g(x) is represented as δx.

[0107] f(x) is represented as -rxln(x) in the Norton-Simon model, and g(x) is represented as δln(x) in the Norton-Simon model;

[0108] f(x) is represented as -rxln(x) in the Emax model, and g(x) is represented as...

[0109] The tracking error for the designed tumor volume is:

[0110] e(t) = x(t) - x d (t); (6)

[0111] Where x d This is the expected value for tumor growth, with a maximum value of 1;

[0112] The first derivatives of formulas (6) and (5):

[0113]

[0114] Design a control law u based on the conventional STC algorithm:

[0115]

[0116] Where k1 and k2 are adjustable gain parameters, and e represents a finite-time convergence function.

[0117] In the control law formula (8), if k1 is chosen to be sufficiently large, and k2 > D, the control law can guarantee finite-time convergence. The sign function `sign(e)` can decompose the sign of a function. In mathematics and computer operations, its function is to determine the sign (positive or negative) of a number. When e > 0, `sign(e) = 1`; when e = 0, `sign(e) = 0`; when e < 0, `sign(e) = -1`.

[0118] In step 4 above, to avoid unnecessary chattering and improve the steady-state of the cell drug delivery system, the discontinuous term k2 in the STC algorithm is removed, and a control law u based on a hybrid SCT and MBSTC algorithm is designed:

[0119]

[0120] Where k1 and k2 represent the parameters of the super-twist controller, k1>0, k2>0, ε represents the adjustable parameter, and e represents the finite-time convergence function.

[0121] Furthermore, substituting formula (9) into formula (7), we get:

[0122]

[0123] Where η1=e, e represents a finite-time convergent function that converges to the optimal solution within a finite time. η2 is the calculus of η1 with time as the drug is administered, that is, the calculus of the system state with time as the drug is administered.

[0124] Figure 2(a) illustrates the tumor volume response process using the STC controller. Figure 2(b) illustrates the tumor volume response process using the SCT-based and MBSTC controllers.

[0125] III. Stability Analysis of Tumor Cell Inhibition Drug Delivery Control System

[0126] In step 5 above, a quadratic-like Lyapunov function is used to perform stability analysis on the tumor cell inhibition drug delivery control system under constant and variable perturbations to ensure asymptotic stability of the system.

[0127] First definition: Given a vector x = [x1, x2, x3, ..., x...] n ]∈R n and the constant τ i >0, i=1,2,…,n. If p∈R, and definition Then the function R n →R: is called homogeneous of degree p, where τ=[τ1,τ2,…,τ n [] represents the weights of the states. R is a matrix function, which is positive definite. n →R, see below for explanation.

[0128] The symbol "→" means that the quantity on the left of the symbol is replaced by the quantity on the right of the symbol.

[0129] First Lemma: Positive Definite Functions Rn →R and function Φ(x):R n →R For the same dilation weights, R has the same uniformity. There exists a constant and If is positive definite, then where k ≥0.

[0130] Second Lemma: Assume 0<a≤1, then

[0131] |[x] a -[y] a |≤2 1-a |x-y| a

[0132] Third Lemma: Let m>0, n>0, then for it can be obtained that:

[0133]

[0134] where h(x,y) is a positive function.

[0135] Fourth Lemma: Let b≥1, then for the following holds

[0136] |[x] b -[y] b |≤b(2 b-2 +2)(|x-y| b +|x-y||y| b-1 (a)

[0137] |[x] b -[y] b |≥2 1-b |x-y| b (b)

[0138] The states η₁ and η₂ of the system will approach the following region:

[0139]

[0140] where k₁ and k₂ are positive constants, and φ∈(0,1) is a constant that must be sufficiently small.

[0141] Obviously, the system state η₁ is bounded by , for example, the tumor volume error e is bounded. By appropriately adjusting the parameters k₁ and ε, the tumor volume error e can be reduced to an arbitrarily small value, thereby ensuring the accuracy of the cancer chemotherapy process.

[0142] Definition: x1 = η1 and The system dynamics formula (10) can be restated as follows:

[0143]

[0144] Where a1 = k1, a2 = k2 / k1.

[0145] To simplify formula (12), we define:

[0146] z1 = -[x1] 1+ε +x2,

[0147]

[0148] Then, the reconstruction of system dynamics (12):

[0149]

[0150] Dependence on Lemma 2 and The facts lead to the following conclusions.

[0151]

[0152] Applying Lemma 4(a), we get:

[0153]

[0154] in

[0155] To ensure the stability of system (14), the Lyapunov function is chosen as follows:

[0156] V(x1,x2)=W1(x1,x2)+W2(x2) (17)

[0157] in Meanwhile, along system (14), the time derivative of V(x1, x2) is as follows:

[0158]

[0159] use And choose a2≥2

[0160]

[0161] By using Lemma 3 and (15), we can obtain:

[0162]

[0163] Where γ1 is a positive constant.

[0164] Substituting equation (20) into (19), we get

[0165] Similarly, the second item can be rewritten.

[0166]

[0167] The following can be calculated simply:

[0168]

[0169] According to Lemma 3, we can obtain:

[0170]

[0171] Where γ2 is a positive constant.

[0172] Similarly, we can conclude that:

[0173]

[0174] γ3 is a positive constant.

[0175] In addition, With the help of Lemma 4(b), it is obvious

[0176]

[0177] Substituting (24), (25), and (26) into (22) yields:

[0178]

[0179] Using (21) and (27), (18) can be written as:

[0180]

[0181] In addition, the constant a1 can be chosen as follows:

[0182]

[0183] Substituting (29) into (28) yields:

[0184]

[0185] in

[0186] Based on assumption 1, we can obtain:

[0187]

[0188] The region Ω is then demonstrated to be achievable within a finite time using the next two steps.

[0189] Step 1: In this step, we will prove... And region Q1 is constructed as follows:

[0190]

[0191] because achievable

[0192]

[0193] From definition 1, we obtain and The 1-γ degree is homogeneous and depends on the expansion weight (1, 1+ε).

[0194] By using Lemma 1, we can arrive at the following conclusion:

[0195]

[0196] Substituting (32) into (31) yields:

[0197]

[0198] Based on facts Formula (33) can be rewritten as

[0199]

[0200] However, when There is no guarantee that the state can escape from region Q1.

[0201] Therefore, a larger region Q2 should be determined. For any initial state (x1(0), x2(0)) ∈ Q2, this region ensures the existence of a time instance T such that (x1, x2) ∈ Q2. Q2 is defined as:

[0202]

[0203] Step 2: Based on the above analysis, assuming it can be proven that Q1 is a subset of Q2, the result... Derivation

[0204] Considering Definition 1, H(x1,x2) is a homogeneous 2+ε degree with respect to the inflation weights (1, 1+ε). Using Lemma 1, we can derive the following:

[0205]

[0206] The above formula can be restated as:

[0207]

[0208] Therefore, from the above formula, we can conclude that (x1,x2)∈Q2, that is...

[0209] In other words, there exists a finite-time instance T such that V(x1,x2)≤K.

[0210] When t≥T, we can obtain:

[0211]

[0212] because a1 = k1, from the above formula we can deduce:

[0213]

[0214] On the other hand, when t≥T, we get:

[0215]

[0216] Considering x1 = η1, it is easy to conclude that:

[0217]

[0218] Therefore, it can be easily deduced from (37) and (38) that the system states η1 and η2 will be driven and converge to the region Ω in the finite time case.

[0219] The fractional power parameter ε can be obtained from Select Except for 0.

[0220] when When ε = 0, the cancer chemotherapy model control scheme based on the smooth super-twisting algorithm degrades to a standard first-order sliding mode control scheme. When ε = 0, the cancer chemotherapy model control scheme based on the smooth super-twisting algorithm becomes PI control. In view of this, the tumor cell model control based on the smooth super-twisting algorithm designed in this invention can be regarded as a non-smooth controller between traditional first-order sliding mode control and PI controller.

[0221] Furthermore, due to the impact of sampling time on the digital application of the controller, the anti-interference performance of first-order sliding mode control may not be superior to that of non-smooth controllers in practical situations. Thanks to the careful selection of parameter ε, the proposed cancer chemotherapy controller based on the smooth super-twisting algorithm not only exhibits smaller drug use oscillations than standard first-order sliding mode control but also demonstrates stronger anti-interference performance.

[0222] Researchers investigated the application of a super-torsional sliding mode control algorithm in a nonlinear model of a brain tumor drug delivery system to stabilize the closed-loop system, suppress uncertainties and disturbances, reduce chattering, and optimize drug dosage. Simulation results show that, under conditions of system uncertainty and disturbances, adjusting the concentration and rate of drug administration can effectively improve the drug delivery effect.

[0223] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A method for the controlled administration of a drug suitable for the inhibition of tumor cells, characterized in that, Includes the following steps: Constructing a mathematical model of tumor cells; The control target is to use specific administration times and / or dosages to ensure that the tumor cell model can control the growth pattern of tumor volume; Based on the defined control objective, a first drug delivery controller model suitable for tumor cell inhibition is designed using a conventional super-twisted control algorithm, and a control law based on the conventional super-twisted control algorithm is designed. A second drug delivery controller model suitable for tumor cell inhibition is designed based on the model smoothing super-twisting control algorithm and the conventional super-twisting control algorithm. A control law based on a hybrid of the conventional super-twisting control algorithm and the model smoothing super-twisting control algorithm is also designed. In the presence of external disturbances, a second drug controller model suitable for tumor cell suppression is ; in, Indicates tumor volume, Indicates control input, This indicates external interference. Represents a tumor cell model, in which In the log-mortality model, it is represented as , In the log-mortality model, it is represented as , In the Norton-Simon model, it is represented as , In the Norton-Simon model, it is represented as , In the Emax model, it is represented as , In the Emax model, it is represented as ; The control law design based on a hybrid of conventional super-twist control algorithm and model-smooth super-twist control algorithm is as follows: ; in , Indicates the parameters of the super-twist controller. , , The parameter is adjustable, and e represents the finite-time convergent function. .

2. The drug administration control method for tumor cell inhibition as described in claim 1, characterized in that, The tumor cell mathematical model includes at least a logarithmic cell death model. Norton-Simon model Emax model ; Where x is the tumor volume, r is the tumor volume growth rate, δ represents the coefficient related to the amount of drug used, λ represents the model constant, and u(t) represents the drug concentration controlled at time t.

3. The drug administration control method for tumor cell inhibition as described in claim 1, characterized in that, Without considering external interference, the first-line drug delivery control model suitable for tumor cell inhibition is: .

4. The drug administration control method for tumor cell inhibition as described in claim 1, characterized in that, The control law design based on the conventional super-twist control algorithm is as follows: : ; in and It is an adjustable gain parameter, and e represents a finite-time convergence function.

5. The drug administration control method for tumor cell inhibition as described in claim 1, characterized in that, The tracking error for tumor volume is defined as: ;in This is the expected value for tumor growth, with a maximum value of 1; The first derivative of the tracking error and dosing control model is: Substituting the control law based on a hybrid of conventional and model-smoothed super-twisted control algorithms into the formula corresponding to the tracking error, we obtain the system dynamics formula: ; in , , e represents a finite-time convergent function that converges to the optimal solution within a finite time interval. yes The integral expression of with time of drug administration.

6. The method for controlling drug administration to inhibit tumor cells as described in any one of claims 1 to 5, characterized in that, It also includes the following steps: 5) The second drug delivery controller model is subjected to stability analysis by using a quadratic-like Lyapunov function under constant and variable perturbations to ensure the asymptotic stability of the system.

7. The drug administration control method for tumor cell inhibition as described in claim 6, characterized in that, The stability analysis includes the following steps: Based on the first definition and the first to fourth lemmas, we prove the state of the system. and It will approach the following area: ; in and It is a positive constant, and It is a constant that must be small enough; The first definition is: given a vector and constants .if , and ;definition Then the function ,in These are the weights of the states, and R is a positive definite matrix function; The first lemma states: positive definite functions sum function For the same inflation weight Having the same uniformity, there exists a constant. ,and ;if If it is positive definite, then ,in ; The second lemma states: Assume ,but , ; The third lemma is: Let m>0, n>0, then for ∀x, y∈R, we have: ; in It is a positive function; The fourth lemma is: Let b ≥ 1, then for ∀x, y ∈ R, the following holds: ; ; prove , And region Q1 is constructed as follows: because , can be obtained From the first definition, we obtain and of The degree is homogeneous, and the expansion weight (1, )related; By using the first lemma, we can arrive at the following inequality conclusions: Substituting the conclusion of the inequality into get: Based on facts get: ; For any initial state This region ensures the existence of a time instance T, such that , ; Q2 is defined as: Considering the first definition, and It's about the inflation weight. of Next, in order; Using the first lemma, we obtain: Restate the conclusion obtained using the first lemma to get: Therefore, we obtain , ; Alternatively, there exists a finite-time instance T such that , ; when We can obtain: because , Therefore, we can conclude that: On the other hand, when At that time, we obtained: Considering Therefore, we can conclude that: The system state can be determined over a finite amount of time. and It will be driven and converge to the region Ω.

Citation Information

Patent Citations

  • Super-distortion control-based DC-DC converter chaotic control method and system, and medium

    CN109742941A

  • Isogeometric simulation system for studying inhibition of chemotherapeutic drugs on tumor growth

    CN113468827A